nature portfolio

Corresponding author(s):	Giovanni Traverso
Last updated by author(s):	Oct 19, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

_				
C -	トつ	+1	ct	ics
	п		``	11 >

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
X	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
So	ftware and code

Software and code

Policy information about availability of computer code

Data collection

Tecan i-control plate reader software (version 2.0.10.0) was used for measurement and collection of fluorescence, absorbance and luminescence data. Instron Bluehill software (version 3.11.1209) was used for collection of mechanical testing data.

Data analysis

GraphPad Prism (Version 9.3.0) was used for statistical analysis of data. Agilent MassHunter software (version B10.1) was used to analyze pharmacokinetics data.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All the data supporting the results in this study are available within the paper and its Supplementary Information. Source data for main figures are provided within the paper. Additional data may be requested from the authors.

Human rese	arch parti	cipants			
Policy information	about <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.			
Reporting on sex	and gender	N/A			
Population chara	acteristics	N/A			
Recruitment		N/A			
Ethics oversight		N/A			
Note that full informa	ation on the appr	roval of the study protocol must also be provided in the manuscript.			
Field-spe	ecific re	eporting			
Please select the o	ne below that i	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
X Life sciences		Behavioural & social sciences			
For a reference copy of	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scier	ncas sti	udy design			
		points even when the disclosure is negative.			
Sample size		or animal studies were based on prior work (Refs. J. Liu, et al. Nat. Commun., 2017; A. C. Anselmo, et al. Adv. Mater. 2016; X. Commun. 2019) without using statistical methods to pre-determine sample sizes.			
Data exclusions	No data were e	excluded.			
Replication	All experiment	al data were replicated at least 3 times in independent experiments.			
Randomization	Animals were randomized to treatment groups. Samples and measurements were prepared and collected in a randomized manner.				
Blinding	Data collection and analysis were not performed blind to the conditions of the experiments, because the same scientists designed and carried out the experiments.				
D = := = := ! :=	- £				
<u> </u>		pecific materials, systems and methods			
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & ex	perimental s	systems Methods			
n/a Involved in the study n/a Involved in the study					
Antibodies		ChIP-seq			
		Flow cytometry			
	Palaeontology and archaeology MRI-based neuroimaging				
Animals and other organisms					
Clinical dat	ta esearch of conce	rn			

Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>

Cell line source(s)

All cell lines were sourced from ATCC. From ATCC: HT-29 was sourced from a female patient; Caco-2 was sourced from a male patient; Hepa 1-6 was sourced from a C57/L mouse, and CV-1 was sourced from a male adult African green monkey.

HT-29 and Caco-2 cells were authenticated by ATCC using Short Tandem Repeat (STR) analysis as described in 2012 in ANSI Authentication Standard ASN-0002. Hepa1-6 and CV-1 cells were not authenticated.

All cell lines tested negative for mycoplasma. Mycoplasma contamination

Commonly misidentified lines (See <u>ICLAC</u> register)

Laboratory animals

N/A

Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

Veterinary Medicine) and male or female Sprague-Dawley rats (>400 g, sourced from Charles River, strain code 001) were used. Due to limited supplies of large >400 g rats, rats were used regardless of age.

Wild animals The study did not involve wild animals.

Data reported in this study are not sex-specific and therefore no sex-specific analysis was conducted. Reporting on sex

Field-collected samples The study did not involve samples collected from the field.

Ethics oversight All animal studies were performed only after Massachusetts Institute of Technology Committee on Animal Care review and ethical

approval and under veterinary supervision. The Massachusetts Institute of Technology Division of Comparative Medicine provided

Female Yorkshire pigs aged 3-7 months (50-100 kg, sourced from Animal Biotech Industries, Inc. or Tufts University School of

guidance and training.

Note that full information on the approval of the study protocol must also be provided in the manuscript.